Last reviewed · How we verify
PBMC immunomodulated with IFNt
At a glance
| Generic name | PBMC immunomodulated with IFNt |
|---|---|
| Sponsor | Nadezhda Women's Health Hospital |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effects of Intrauterine Administration of Autologous PBMC Modulated With IFNt on Endometrial Cell Populations (NA)
- Effect of Intrauterine Administration of Autologous PBMC Modulated With IFNt on IVF Outcome (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PBMC immunomodulated with IFNt CI brief — competitive landscape report
- PBMC immunomodulated with IFNt updates RSS · CI watch RSS
- Nadezhda Women's Health Hospital portfolio CI